Full Press Release Details
CAMBRIDGE, Mass.,Oct. 14, 2025/PRNewswire/ --MetaVia Inc.(Nasdaq:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that President and Chief Executive Officer, Hyung Heon Kim, will present a company overview at the H.C. Wainwright Liver Disease Virtual Conference taking place October 21-22, 2025.
Mr. Kim and Marshall H. Woodworth, Chief Financial Officer, will also participate in one-on-one meetings. Institutional investors who are registered for the conference can log intowww.hcwevents.comto request a meeting with the company.
To schedule a meeting with management outside of the conference, investors can contact Michael Miller at[email protected].
About MetaViaMetaViaInc. is a clinical-stage biotechnology company focused on transformingcardiometabolicdiseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-AssociatedSteatohepatitis(MASH). DA-1726 is a noveloxyntomodulin(OXM) analogue that functions as aglucagon-likepeptide-1 receptor (GLP1R) andglucagonreceptor (GCGR) dualagonist.OXMis a naturally-occurring gut hormone that activates GLP1R andGCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1Ragonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119)agonistthat promotes the release of key gut peptidesGLP-1,GIP, andPYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepaticsteatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visitwww.metaviatx.com.